Metabolic Solutions Development Company
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Metabolic Solutions Development Company
Oncology’s Hold Over The Pharma Pipeline Increases As Growth Slows
The rate of growth of the pharma pipeline slowed last year as oncology and rare diseases tightened their grip on R&D. There are also further signs of China’s rise in importance in the industry.
Cirius Suspects Insulin Resistance Is Underlying Key To NASH
The former Octeta is expanding the ongoing Phase IIb study of its second-generation insulin sensitizer. An insulin sensitizer with a better safety profile than first-generation drugs like Actos may provide a backbone therapy for NASH, the company believes.
With Phase III NASH Endpoints In Place, Intercept May Reach Market By 2018
Although it is the first company to reach Phase III in non-alcoholic steatohepatitis, Intercept has a long road ahead with a 2,500-patient trial that will include a 72-week interim look that could lead to initial approval in the U.S. and EU.
MSDC avoids the glitazone as PhIIb insulin sensitiser dances toward partners
The private US firm Metabolic Solutions Development Company (MSDC) has presented Phase IIb data for its insulin sensitiser drug candidate that it says has a novel metabolic action that should avoid the side-effects that have damaged the glitazone drug class.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.